Larissa C.Bergin

Larissa Bergin's practice addresses the antitrust concerns arising from M&A matters, joint ventures, federal investigations, and commercial practices. She has overseen the antitrust aspects of corporate M&A, including due diligence, risk-shift negotiations, Hart-Scott-Rodino (HSR) filings, Second Requests, investigational hearings, integration planning, and consent decrees with federal agencies. She works with clients in a variety of industries, including the technology, health care, retail, and pharmaceutical sectors. Many of Larissa's clients have international reach, and she has been involved in matters that require advocacy before governments throughout Asia, the EU, and North America.

Larissa also advises clients on corporate contracting and operational practices that can run afoul of the antitrust laws, including supplier agreements, information sharing, competitive benchmarking, and Robinson-Patman Act pricing matters.

At the start of her career, Larissa clerked at the U.S. Court of Federal Claims, where she addressed intellectual property, tax, and government contract issues, including Serco, Inc. v. United States (also referred to as the Alliant protest), a bid-protest case involving a $50 billion procurement for government-wide information technology and services.

Larissa is a member of the Antitrust Section of the American Bar Association and is chair of the Food, Drug and Cosmetics Law Section of the New York State Bar Association. She is admitted in the New York, Connecticut, and District of Columbia bars.

Larissa has been quoted on MSNBC regarding how Obamacare has affected M&A activity and in Getting the Deal Through on generic drug approval.